BB's Stock Haven

[JohnnyRothrock]

NAOV dd: CEO said in June PR that no one can convert and shares …so no dilution..unil their AS raise proposal goes through mid August. ::

“The company will be asking stockholders to approve a proposal to increase the number of common shares authorized for issuance from 24.1 million shares to 40 million shares at an Annual Meeting of Stockholders to be held on August 17, 2021. The increase is being requested to provide the company with a sufficient number of authorized shares to meet its existing preferred stock conversion obligations and warrant and option obligations and leave the company with an additional capacity to pursue a modest level of strategic transactions at the Board’s discretion if such opportunities arise.

As of March 31, 2021, the company had approximately 24.1 million shares of common stock authorized as well as issued and outstanding leaving no capacity to meet future potential needs for shares upon conversion of certain shares of Series C, Series D and Series E Preferred Stock or the exercise of outstanding warrants and stock options.

“There is presently no capacity for issuing new shares of common stock to meet our obligations under existing derivative instruments that may convert to equity,”


https://www.otcmarkets.com/stock/NAOV/news/story?e&id=1913946


…wow….meaning w maxed 25 mil OS and AS….dis could get nuts next week. Cause if 100% of participants chose to keep using their product….cause at end of day who wants to stick something up your thing (noooooooooooooooooooooooooo! lol) : and this does a better job and easy for non medical people to do like family…..the upside run here could be $10+ w this non diluting SS.

From todays big PR:


“This independent study is further proof of the effectiveness and applicability of our UroShield device in reducing the incidence of urinary tract infections and the pain and discomfort caused by urinary catheters,” stated Brian Murphy, Chief Executive Officer of NanoVibronix, Inc. “As we would expect, the patient experiences in the study were statistically significant, with all responding patients reporting that our device was simple, easy to use and materially benefitted them. The patient experiences were so profoundly positive that 100% of the study’s participants are continuing to use the device following the conclusion of the study.”

Murphy added, “Importantly, the study was conducted in real world settings, including private residences and long-term care facilities. Study participants, who often relied on family members and other assistants, achieved positive outcomes without the benefit of trained clinicians and skilled care givers, reinforcing our assertion of the ease of use of the UroShield device.”